The final phase of the human genome project billed as potentially the greatest advance in the history of medical science has erupted into a tense war of words between Federal researchers racing to complete the task and the flamboyant president of a biotech startup who wants to profit by giving drug companies an early, private look at the genetic data.
Patent issue divides genome researchers drug companies.